Pyrimidine derivatives with antitubercular activity
V Finger, M Kufa, O Soukup, D Castagnolo… - European Journal of …, 2023 - Elsevier
Small molecules with antitubercular activity containing the pyrimidine motif in their structure
have gained more attention after three drugs, namely GSK 2556286 (GSK-286), TBA-7371 …
have gained more attention after three drugs, namely GSK 2556286 (GSK-286), TBA-7371 …
Overview of recent strategic advances in medicinal chemistry
G Wu, T Zhao, D Kang, J Zhang, Y Song… - Journal of medicinal …, 2019 - ACS Publications
Introducing novel strategies, concepts, and technologies that speed up drug discovery and
the drug development cycle is of great importance both in the highly competitive …
the drug development cycle is of great importance both in the highly competitive …
Identification of hydantoin based Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) inhibitors as antimycobacterial agents using computational tools
Tuberculosis (TB) is one of the emerging infectious diseases in the world. DprE1 (
Decaprenylphosphoryl-β-d-ribose 2′-epimerase), an enzyme accountable for …
Decaprenylphosphoryl-β-d-ribose 2′-epimerase), an enzyme accountable for …
Recent Advances of DprE1 Inhibitors against Mycobacterium tuberculosis: Computational Analysis of Physicochemical and ADMET Properties
PSM Amado, C Woodley, MLS Cristiano, PM O'Neill - ACS omega, 2022 - ACS Publications
Decaprenylphosphoryl-β-d-ribose 2′-epimerase (DprE1) is a critical flavoenzyme in
Mycobacterium tuberculosis, catalyzing a vital step in the production of lipoarabinomannan …
Mycobacterium tuberculosis, catalyzing a vital step in the production of lipoarabinomannan …
Tuberculosis drug discovery: A decade of hit assessment for defined targets
More than two decades have elapsed since the publication of the first genome sequence of
Mycobacterium tuberculosis (Mtb) which, shortly thereafter, enabled methods to determine …
Mycobacterium tuberculosis (Mtb) which, shortly thereafter, enabled methods to determine …
In Silico Development of Novel Benzofuran-1,3,4-Oxadiazoles as Lead Inhibitors of M. tuberculosis Polyketide Synthase 13
Benzofuran and 1, 3, 4-oxadiazole are privileged and versatile heterocyclic
pharmacophores which display a broad spectrum of biological and pharmacological …
pharmacophores which display a broad spectrum of biological and pharmacological …
Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs
SR Green, SH Davis, S Damerow, CA Engelhart… - Nature …, 2022 - nature.com
Tuberculosis is a major global cause of both mortality and financial burden mainly in low
and middle-income countries. Given the significant and ongoing rise of drug-resistant strains …
and middle-income countries. Given the significant and ongoing rise of drug-resistant strains …
Promiscuous targets for antitubercular drug discovery: The paradigm of DprE1 and MmpL3
The development and spread of Mycobacterium tuberculosis multi-drug resistant strains still
represent a great global health threat, leading to an urgent need for novel anti-tuberculosis …
represent a great global health threat, leading to an urgent need for novel anti-tuberculosis …
DprE1 inhibitors: enduring aspirations for future antituberculosis drug discovery
DprE1 is a crucial enzyme involved in the cell wall synthesis of Mycobacterium tuberculosis
and a promising target for antituberculosis drug development. However, its unique structural …
and a promising target for antituberculosis drug development. However, its unique structural …
Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions
B Gold, J Zhang, LL Quezada, J Roberts… - ACS infectious …, 2022 - ACS Publications
Rising antimicrobial resistance challenges our ability to combat bacterial infections. The
problem is acute for tuberculosis (TB), the leading cause of death from infection before …
problem is acute for tuberculosis (TB), the leading cause of death from infection before …